Drugs / M108
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04894825 | Jun 2021 → Jul 2024 | — | FutureGen Biopharmaceutical (Beijing) Co., Ltd | Unknown | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06177041 | Dec 2023 → Jan 2027 expected | gastroesophageal junction adenocarcinoma | FutureGen Biopharmaceutical (Beijing) Co., Ltd | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | M108 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06177041 ↗ |
| Modality | Monoclonal antibody | “M108 is a monoclonal antibody specific for gastric and gastroesophageal adenocarcinomas.” NCT04894825 ↗ |
| Route | Intravenous | “IV infusion Q3W” NCT04894825 ↗ |